<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02893540</url>
  </required_header>
  <id_info>
    <org_study_id>RJH-Oncol-Metronomic</org_study_id>
    <nct_id>NCT02893540</nct_id>
  </id_info>
  <brief_title>Metronomic Versus Conventional Chemotherapy in as Maintenance Treatment in mCRC</brief_title>
  <official_title>Capecitabine Metronomic Chemotherapy Versus Conventional Chemotherapy as Maintenance Treatment in Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The optimum regimen of maintenance treatment after first-line chemotherapy in patients with
      metastatic colorectal cancer (mCRC) is unknown. This study was designed to determine the
      efficacy and safety of maintenance treatment with capecitabine metronomic chemotherapy versus
      conventional chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this Prospective, open-label, randomised controlled trial, the investigators will recruit
      250 mCRC patients who have finished 18 to 24 weeks first-line chemotherapy and disease
      evaluation is SD, PR or CR. Then, the patients will be randomised into two group. The
      experimental group, capecitabine metronomic chemotherapy versus capecitabine conventional
      chemotherapy as control group. These treatment regimens will be continued until progression,
      death, or an unacceptable adverse event.

      The primary endpoint is progression-free survival (PFS). Secondary endpoints are overall
      survival (OS), quality of life (QOL) and toxic effects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS1</measure>
    <time_frame>4 months</time_frame>
    <description>from randomizing to progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>20 months</time_frame>
    <description>from signing informed consent form to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL</measure>
    <time_frame>20 months</time_frame>
    <description>QLQ-C30</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Metronomic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>accept capecitabine metronomic chemotherapy (500mg, twice per day, everyday)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>accept capecitabine conventional chemotherapy (1000mg/m2, twice per day for 14 days, every 21 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>we are going to compare two maintenance treatment models with capecitabine in this study</description>
    <arm_group_label>Metronomic</arm_group_label>
    <arm_group_label>Conventional</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological proof of colorectal cancer (in case of a single metastasis, histological
             or cytological proof of this lesion should be obtained);

          -  Distant metastases (patients with only local recurrence are not eligible);

          -  Unidimensionally measurable disease (&gt; 1 cm on spiral CT scan or &gt; 2 cm on chest
             X-ray; liver ultrasound is not allowed). Serum CEA may not be used as a parameter for
             disease evaluation;

          -  In case of previous radiotherapy, at least one measurable lesion should be located
             outside the irradiated field.

        Exclusion Criteria:

          -  Prior adjuvant treatment for stage II/III colorectal cancer ending within 6 months
             before the start of induction treatment;

          -  Any prior adjuvant treatment after resection of distant metastases;

          -  Previous systemic treatment for advanced disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yifeng Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Rui Jin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>HAO LI, MD，Ph.D</last_name>
    <phone>86-15000929050</phone>
    <email>drlihao@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>JUN ZHANG, MD，Ph.D</last_name>
    <phone>86-18917762326</phone>
    <email>junzhang@188.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Rui Jin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yifeng Wang</last_name>
      <phone>8621-64370045</phone>
      <phone_ext>665879</phone_ext>
      <email>wyfkjc@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, de Jongh FE, Erdkamp FL, Erjavec Z, van der Torren AM, Tol J, Braun HJ, Nieboer P, van der Hoeven JJ, Haasjes JG, Jansen RL, Wals J, Cats A, Derleyn VA, Honkoop AH, Mol L, Punt CJ, Koopman M. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015 May 9;385(9980):1843-52. doi: 10.1016/S0140-6736(14)62004-3. Epub 2015 Apr 7.</citation>
    <PMID>25862517</PMID>
  </reference>
  <reference>
    <citation>Luo HY, Li YH, Wang W, Wang ZQ, Yuan X, Ma D, Wang FH, Zhang DS, Lin DR, Lin YC, Jia J, Hu XH, Peng JW, Xu RH. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Ann Oncol. 2016 Jun;27(6):1074-81. doi: 10.1093/annonc/mdw101. Epub 2016 Mar 2.</citation>
    <PMID>26940686</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2016</study_first_submitted>
  <study_first_submitted_qc>September 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>September 15, 2016</last_update_submitted>
  <last_update_submitted_qc>September 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Hao Li</investigator_full_name>
    <investigator_title>MD, Ph.D</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

